Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Dimethyl fumarate is coming of age

Nature Reviews Neurology volume 12, pages 436–437 (2016)Cite this article

Subjects

Recently published findings from the ENDORSE study provide 5 years of randomized safety and efficacy data for two doses of dimethyl fumarate (DMF) in multiple sclerosis. The report complements results from the pivotal CONFIRM and DEFINE trials; however, postmarketing data from clinical practice is needed to complete the risk–benefit profile of DMF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098–1107 (2012).

    Article  CAS  Google Scholar 

  2. Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–1097 (2012).

    Article  CAS  Google Scholar 

  3. Ralf Gold, Douglas, L. Arnold, Amit Bar-Or et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult. Scler. http://dx.doi.org/10.1177/1352458516649037 (2016).

  4. Tecfidera® Package Insert [online] (Biogen Idec, 2015).

  5. [no authors listed.] TECFIDERA: summary of product characteristics. European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf.

  6. Nast, A. et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. 29, 2277–2294 (2015).

    Article  CAS  Google Scholar 

  7. Brennan, M. S. et al. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. 10, e0120254 PLoS ONE (2015).

    Article  Google Scholar 

  8. Bartsch, T. et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann. Neurol. 78, 501–514 (2015).

    Article  CAS  Google Scholar 

  9. Khatri, B. O. et al. The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult. Scler. Relat. Disord. 4, 377–379 (2015).

    Article  Google Scholar 

  10. Rosenkranz, T., Novas, M. & Terborg, C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 372, 1476–1478 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology/Neuroimmunology, Jaume Sastre-Garriga and Mar Tintoré are at the Centre d'Esclerosi Múltiple de Catalunya, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119–129, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.,

    Mar Tintoré & Jaume Sastre-Garriga

Authors
  1. Mar Tintoré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaume Sastre-Garriga
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors research literature for the article, and provided substantial contribution to discussion of content, writing and editing of the manuscript.

Corresponding author

Correspondence to Mar Tintoré.

Ethics declarations

Competing interests

J.S.-G. has received compensation for consulting services and speaking honoraria from Biogen-Idec, Merck-Serono, Novartis and Teva. M.T. has received compensation for consulting services and speaking honoraria from Almirall, Bayer-Schering, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi and Teva.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tintoré, M., Sastre-Garriga, J. Dimethyl fumarate is coming of age. Nat Rev Neurol 12, 436–437 (2016). https://doi.org/10.1038/nrneurol.2016.106

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.106

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing